Structure–Activity Relationship of Novel Pyrimidine Derivatives with Potent Inhibitory Activities against Mycobacterium tuberculosis

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

(2022) Zhen Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis

(2022) Rong Yao et al.   Microbiology Spectrum

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis

(2022) Mohammad Javad Nasiri et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Tuberculosis Drug Discovery: Challenges and New Horizons

(2022) Guilherme F. S. Fernandes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Anti-tuberculosis treatment strategies and drug development: challenges and priorities

(2022) Véronique A. Dartois et al.   NATURE REVIEWS MICROBIOLOGY

Discovery and Mechanistic Study of Mycobacterium tuberculosis PafA Inhibitors

(2022) Cong Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cosolvent Sites-Based Discovery of Mycobacterium Tuberculosis Protein Kinase G Inhibitors

(2022) Osvaldo Burastero et al.   JOURNAL OF MEDICINAL CHEMISTRY

MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature

(2022) Mohd. Imran et al.   Biomedicines

Pyrimidine derivatives with antitubercular activity

(2022) Vladimir Finger et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Pretomanid for tuberculosis: a systematic review

(2021) Tinne Gils et al.   CLINICAL MICROBIOLOGY AND INFECTION

Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis

(2021) Ju Sang Kim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China

(2021) Xia Yu et al.   Infection and Drug Resistance

OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor

(2020) Norimitsu Hariguchi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline

(2020) Hui Guo et al.   NATURE

3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel

(2019) Hamish S. Sutherland et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)

(2019) Xiaotian Kong et al.   JOURNAL OF MEDICINAL CHEMISTRY

In vitro activity of PBTZ169 against multiple Mycobacterium species

(2018) Jin Shi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents

(2018) Pingxian Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions

(2017) Tiansheng Wang et al.   ACS Medicinal Chemistry Letters

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

(2013) Thomas H. Marsilje et al.   JOURNAL OF MEDICINAL CHEMISTRY